Tempest Therapeutics, Inc. — Form 8-K
Filed August 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
Form 8-K filed 2026-08-24 reports Item 5.02 event (departure of directors/officers or appointment/compensation changes) as of 2026-08-18. The filing provides no specific names, dollar amounts, equity grants, severance terms, or details of any departures or appointments. The actual substantive disclosures are not included in this index page.
Why this rating
Cannot assess impact without actual disclosure details. If material officer departure, could be significant for $30M company; if routine appointment or minor compensation adjustment, routine. Filing stub alone insufficient.
Extracted items
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.